Apontis Pharma AG (APPH.F)

7.98 +0.14 (+1.79%) At close: 09:50PM CEST

Apontis Pharma AG

Alfred-Nobel-Str. 10
Monheim am Rhein 40789
Germany
49 2173 8955 4949
https://apontis-pharma.de

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 177

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Bruno Wohlschlegel	Chairman of Management Board	180.96k	N/A	1968
Mr. Thomas Milz	Chief Product Officer & Deputy Chairman of Management Board	324k	N/A	N/A
Mr. Thomas Zimmermann	Chief Financial Officer	N/A	N/A	N/A
Mr. Harald Weyand	Head of Marketing	N/A	N/A	N/A
Dr. Matthias Wendl	Head of Sales	N/A	N/A	N/A
Ms. Susanne Böhm	Head of HR	N/A	N/A	N/A
Dr. Olaf Randerath	Head of Medicine	N/A	N/A	N/A
Dr. Susanne Endreß	Head of QA, Drug Safety & Regulatory Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. It develops, promotes, and sells a portfolio of single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prevention, as well as respiratory diseases and diabetes. The company was founded in 1946 is headquartered in Monheim am Rhein, Germany.

Corporate governance

Apontis Pharma AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.